CENPA and systemic sclerosis: Anti-Topo I abs were present in 64 (40.5%) SSc patients (lcSSc, 26.3%; dcSSc, 61.9%) anti-CENP were present in 52 (32.9%), all anti-CENPA and anti-CENPB-positive, SSc patients (lcSSc, 46.3%; dcSSc, 14.2%), anti-Ro52 in 21.5%, anti-RP155 in 21 (13.3%), anti-RP11 in 14 (8.9%), anti-Ku in 6 (4.6%), anti-NOR90 in 7 (4.4%), anti-PM-Scl75 in 5 (3.2%), anti-PM-Scl100 in 2 (1.3%), and anti-fibrillarin in 2 (1.3%), and anti-Th/To in 2 (1.3%) SSc patients.